MJA InSight
MJA Careers

Health headlines

Monday, 20 February, 2012
Health headlines cover image

NSAIDs may stop cancer spread
AUSTRALIAN researchers have discovered a key molecular change during cancer metastasis that may be restricted by aspirin and other nonsteroidal anti-inflammatory drugs. The researchers from the Peter MacCallum Cancer Centre in Melbourne identified regulation of PGDH, the key enzyme in prostaglandin catabolism, in endothelial cells of collecting lymphatics as a key molecular change during lymphatic tumour spread. The research, published in Cancer Cell, was reported by the ABC AM program.

Botox for migraine queried
THE UK’s National Institute for Health and Clinical Excellence has published draft guidelines saying there is insufficient evidence for botulinum toxin type A to be included on the National Health Service as a recommended treatment for migraine. It wants the manufacturer to provide better data before making a final decision in June. The finding was reported by BBC News.

Hairdressers’ burden
MANY hairdressers are so burdened by their customers’ stories of domestic struggles they are giving up and getting out of the game, news.com.au reports. A study by Kooweerup Regional Health Services in the Cardinia Shire in Victoria found that hairdressing salons are a unique setting for providing the community, particularly women, with access to health information and increased knowledge of local services. However, survey leader Aileen Thoms told news.com.au that the study produced stories that would challenge any hairdresser.

Food claims challenge
FOOD Standards Australia and New Zealand is seeking submissions for a draft nutrition, health and related claims standard on food products. The agency has expressed concerns about the use of fat-free and percentage fat-free claims, particularly where products with these claims were high in sugar or energy content. The call for submissions was reported by the Sydney Morning Herald.

Fake cancer drug warning
THE US Food and Drug Administration has issued a warning to health care professionals and patients about a counterfeit version of Avastin 400 mg/16 mL, which may have been purchased and used by some medical practices. The FDA said the fake drug does not contain the medicine’s active ingredient, bevacizumab, which my have resulted in patients not receiving needed therapy. Reuters reported the warning, which it said had sparked new alarm over counterfeit medicines.

Posted 20 February 2012